baiya SARS-CoV-2 Vax 2 / Baiya Phytopharm - LARVOL DELTA

Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19 (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: Baiya Phytopharm Co., Ltd.

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Baiya Phytopharm Co., Ltd. | Trial completion date: Jan 2024 ➔ Apr 2024

Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19 (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: Baiya Phytopharm Co., Ltd.

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant. (PubMed, Vaccine) - "The toxicity of Baiya SARS-CoV-2 Vax 2 was further investigated in Jcl:SD rats, which demonstrated that a single dose and repeated doses of Baiya SARS-CoV-2 Vax 2 were well tolerated and no mortality or unanticipated findings were observed. Overall, these preclinical findings support further clinical development of Baiya SARS-CoV-2 Vax 2."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Baiya Phytopharm Co., Ltd. | Trial completion date: May 2023 ➔ Jan 2024 | Trial primary completion date: Nov 2022 ➔ May 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Baiya Phytopharm Co., Ltd. | Trial primary completion date: May 2022 ➔ Nov 2022

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Baiya Phytopharm Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8